AFAP1L2 Antibody
| Code | Size | Price |
|---|
| PSI-5221-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5221-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
AFAP1L2 Antibody: XB130, KIAA1914, CTB-1144G6.4, XB130, Actin filament-associated protein 1-like 2, AFAP1-like protein 2
Application Note:
AFAP1L2 antibody can be used for detection of AFAP1L2 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
AFAP1L2 Antibody: AFAP1L2, also known as XB130, is structurally similar to actin-filament-associated protein (AFAP), containing several SH2- and SH3-binding motifs, two pleckstrin homology domains, a coiled-coil region, and many potential phosphorylation sites. It interacts with and is phosphorylated by c-Src tyrosine kinase. Suppression of AFAP1L2 via siRNA reduced Src activity, IL-8 production, EGF-induced phosphorylation of Akt and GSK3beta, and altered cell cycles in human lung epithelial cells suggesting that AFAP1L2 plays a role as an adaptor in the regulation of Src signal transduction and multiple cellular functions. Recent experiments have shown that AFAP1L2 is highly expressed in thyroid and is the substrate RET/PTC kinase, a thyroid-specific kinase that plays a pathogenic role in papillary thyroid cancer. Down-regulation of AFAP1L2 in these cancer cells reduced Akt activity, inhibiting cell-cycle progression and cancer cell survival in suspension, indicating that AFAP1L2 may be a valuable target in thyroid cancer therapy. At least four isoforms of AFAP1L2 are known to exist.
Background References:
- Xu J, Bai X-H, Lodyga M, et al. XB130, a novel adaptor protein for signal transduction. J. Biol. Chem.2007; 282:16401-12.
- Lodyga M, De Falco V, Bai XH, et al. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. Oncogene2009; 28:937-49.
Buffer:
AFAP1L2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (100%)
Immunogen:
AFAP1L2 antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of human AFAP1L2.
The immunogen is located within the last 50 amino acids of AFAP1L2.
The immunogen is located within the last 50 amino acids of AFAP1L2.
NCBI Gene ID #:
84632
NCBI Official Name:
actin filament associated protein 1-like 2
NCBI Official Symbol:
AFAP1L2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_001001936
Protein GI Number:
50897850
Purification:
AFAP1L2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
Swissprot #:
Q8N4X5
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | AFAP1L2 Peptide | PSI-5221P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|